Edition:
United States

Nippon Kayaku Co Ltd (4272.T)

4272.T on Tokyo Stock Exchange

1,206JPY
20 Jul 2018
Change (% chg)

¥-10 (-0.82%)
Prev Close
¥1,216
Open
¥1,214
Day's High
¥1,219
Day's Low
¥1,196
Volume
672,300
Avg. Vol
669,750
52-wk High
¥1,899
52-wk Low
¥1,143

Latest Key Developments (Source: Significant Developments)

Chugai Pharmaceutical says waiver of claims in patent infringement lawsuit
Wednesday, 11 Apr 2018 02:47am EDT 

April 11 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it has decided to waive its claim in a patent infringement lawsuit against Nippon Kayaku Co Ltd <<<4272.T>>>.Says co filed a lawsuit to the Tokyo District Court on Aug. 17, 2017, demanding the suspension of manufacturing and distribution of the biosimilar of anti-HER2 monoclonal antibody Herceptin® Injection 60 and 150 (Herceptin® Injection) against Nippon Kayaku, the applicant for marketing approval of the biosimilar of Herceptin® Injection, citing such party's infringement of the application patents for the treatment of breast cancer owned by Genentech Inc.  Full Article

Nippon Kayaku initiates phase II clinical trials on NK105 for treatment of breast cancer
Tuesday, 20 Feb 2018 10:32pm EST 

Feb 21 (Reuters) - Nippon Kayaku Co Ltd <4272.T>:Says it initiated phase II clinical trials on NK105 for treatment of breast cancer .  Full Article

Nippon Kayaku unit acquires 100 pct stake in RaySpec
Wednesday, 27 Dec 2017 02:17am EST 

Dec 27(Reuters) - Nippon Kayaku Co Ltd <4272.T>:Says its consolidated subsidiary Polatechno Co Ltd <<<4239.T>>> acquired 100 percent stake in the United Kingdom-based firm RaySpec Limited, on Dec. 26.  Full Article

Chugai Pharmaceutical says lawsuit on patent infringement concerning Herceptin® injection and petition for provisional disposition order
Friday, 8 Sep 2017 02:26am EDT 

Sept 8 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says co has filed a lawsuit and a petition for provisional disposition order against Nippon Kayaku Co.,Ltd <<<4272.T>>>, demanding the suspension of manufacturing and distribution of the biosimilar of anti-HER2 monoclonal antibody Herceptin® injection 60 and 150 (Herceptin® injection) .Genentech Inc, a U.S.-based firm, is a patent holder and co is the exclusive licensee of Herceptin® injection .Says co and Genentech are the co-plaintiff of the lawsuit.  Full Article

BRIEF-Chugai Pharmaceutical says waiver of claims in patent infringement lawsuit

* Says it has decided to waive its claim in a patent infringement lawsuit against Nippon Kayaku Co Ltd